Completed PHASE1 INTERVENTIONAL NCT00532012

Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®

An Open-Label, Partially Randomized, Cross-Over, Monocentric Phase I Study Evaluating the Pharmacokinetic Profile of RhuDex® in Order to Determine Optimum Doses of Meglumine and RhuDex®

Sponsor: MediGene

Conditions Pharmacokinetics

Interventions RhuDex®

Updated 5 times since 2017 Last updated: Jul 15, 2008 Started: Sep 30, 2007 Primary completion: Oct 31, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Pharmacokinetics, this trial is completed. The trial is conducted by MediGene and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MediGene

Data source: MediGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edinburgh, United Kingdom